Lack of association between seborrheic dermatitis and SARS-CoV-2 outcomes
J Eur Acad Dermatol Venereol
.
2022 Mar;36(3):e177-e179.
doi: 10.1111/jdv.17825.
Epub 2021 Dec 4.
Authors
U Rakita
1
,
T Kaundinya
2
,
A Guraya
3
,
K Nelson
4
,
B Maner
5
,
J Manjunath
4
,
G Schwartzman
4
,
B Lane
6
,
J I Silverberg
4
Affiliations
1
Chicago Medical School, Rosalind Franklin University, North Chicago, IL, USA.
2
Northwestern Feinberg School of Medicine, Chicago, IL, USA.
3
Midwestern University Chicago College of Osteopathic Medicine, Downers Grove, IL, USA.
4
Department of Dermatology, George Washington School of Medicine, Washington, DC, USA.
5
Ross University School of Medicine, St. Michael, Barbados.
6
Michigan State University College of Human Medicine, East Lansing, MI, USA.
PMID:
34807473
PMCID:
PMC9011498
DOI:
10.1111/jdv.17825
No abstract available
Publication types
Letter
MeSH terms
Antifungal Agents / therapeutic use
COVID-19*
Dermatitis, Seborrheic* / complications
Dermatitis, Seborrheic* / drug therapy
Humans
Malassezia*
SARS-CoV-2
Substances
Antifungal Agents